Clemens B. Caspar - Concepedia

Author

Clemens B. Caspar

Also Known As

C B Caspar, C Caspar, C. B. Caspar, C. Caspar, C., Caspar, C.B. Caspar, Clemens B Caspar, Clemens B. Caspar, Clemens Caspar

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Kantonsspital Baden Kantonsspital Graubünden Kantonsspital St. Gallen University Hospital of Bern Swiss Group For Clinical Cancer Research

About

Clemens B. Caspar is an author at Kantonsspital Baden specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.3K
2	Health Sciences	3	3	671
3	Immunology	2	2	202
4	Microbiology	1	1	58
5	Nephrology	1	1	15

Clemens B. Caspar

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients John M. Timmerman, Debra K. Czerwinski, Thomas A. Davis, Blood	2002	541
Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial Frank J. Hsu, Clemens B. Caspar, Debra K. Czerwinski, Blood	1997	453
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial Rolf A. Stahel, Oliver Riesterer, Alexandros Xyrafas, The Lancet Oncology Surgical OncologyMalignant Pleural MesotheliomaRadiation TherapyMedicineSakk 17/04	2015	196
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. John M. Timmerman, Gita Singh, Gary Hermanson, PubMed Plasmid Dna VaccineImmunodeficienciesImmunologyImmunodominancePathology	2002	179
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK Markus Borner, Dieter Koeberle, Roger von Moos, Annals of Oncology Swiss GroupOncologyGastrointestinal OncologyMedicinePathology	2008	127
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03) Gianfranco Pesce, Dirk Klingbiel, Karin Ribi, European Journal of Cancer Neuro-oncologyRadiation TherapyMedicineCancer ManagementSakk 70/03	2011	77
Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research Dieter Koeberle, Piercarlo Saletti, Markus Borner, Journal of Clinical Oncology	2008	72
Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas John M. Timmerman, Clemens B. Caspar, Stacie Lambert, Blood	2001	65
Idiotype Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formulations Clemens B. Caspar, Shoshana Levy, Ronald Levy Blood	1997	58

Page 1